The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction
Abstract
Introduction: With once-daily administration of tadalafil, dosing and sexual activity would no longer need to be temporally linked for patients with erectile dysfunction (ED). Aim: To evaluate long-term safety and efficacy of tadalafil 5 mg dosed once daily for the treatment of ED. Methods: Patients ≥18 years of age with ED of any functional severity or etiology received tadalafil 5 mg once daily for 1 (N = 234) or 2 (N = 238) years during the open-label extensions of two previously reported studies. Patients who completed the 1-year open-label extension concluded with a 4-week ED treatment-free period. Baseline was defined as prior to receiving any study drug. Main Outcome Measures: Safety measures included adverse events, electrocardiograms, and clinical laboratory measures. Efficacy measures included the International Index of Erectile Function (IIEF)-Erectile Function (-EF), -Intercourse Satisfaction (-IS), and -Overall Satisfaction (-OS) domain scores, and the Global Assessment Questions (GAQ1: improved erections; GAQ2: improved ability to engage in sexual activity). Results: Overall, 208/234 (88.9%) and 139/238 (58.4%) patients completed the 1- and 2-year open-label extensions, respectively. No study drug-related serious adverse events were observed. Treatment-emergent adverse events observed in ≥5% of the patients during the first year of either open-label extension were dyspepsia, headache, back pain, and influenza. No clinically meaningful abnormalities associated with tadalafil were observed for electrocardiograms or clinical laboratory measures. Mean IIEF domain scores improved from baseline to the conclusions of the 1- and 2-year open-label extensions, respectively: -EF, +10.4 and +10.8; -IS, +4.0 and +3.7; and -OS, +3.0 and +3.2. At the conclusion of the 2-year open-label extension, 95.7% and 92.1% of the patients reported positive responses to GAQ1 and GAQ2, respectively. Conclusions: In these long-term, open-label, once-daily dosing studies, tadalafil 5 mg was well tolerated and effective, making it a viable alternative to the current on-demand dosing of tadalafil for men with ED.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The IIEF-EF score improved from baseline by 10.4 and 10.8 in the 1- and 2-year extensions, respectively.”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Porst et al 2008
In the citing paper
“After 2 years, 95.7% of patients reported improved erections (Porst et al 2008).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Porst et al 2008
In the citing paper
“There were 208 of 234 possible patients (88.9%) who completed the 1-year extension and 139 of 238 possible patients (58.4%) who completed the 2-year extension.”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Porst et al 2008
In the citing paper
“In open-label extensions of the two randomized, placebo controlled trials of once-daily tadalafil described above, Porst and colleagues have evaluated the long-term safety and efficacy of once-daily tadalafil 5 mg over 1 and 2 years (Porst et al 2008).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Porst et al 2008
In the citing paper
“Although an impressively positive response, the 2-year GAQ data had a significant dropout rate and likely contained selection bias toward patients who had a positive response.”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Porst et al 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Tadalafil pharmacokinetics in healthy subjects
Forgue, S. T., Patterson, B. E., Bedding, A. W., Payne, C. D., Phillips, D. L., Wrishko, R. E., & Mitchell, M. I. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02553.x · Cited by 284
Research works printed but not linked: 22
- Wespes, 2006, EAU. EAU guidelines on erectile dysfunction: An update, Eur Urol, 49, 806, 10.1016/j.eururo.2006.01.028 · DOI · Paper page
- Hatzimouratidis, 2007, Phosphodiesterase type 5 inhibitors: The day after, Eur Urol, 51, 75, 10.1016/j.eururo.2006.07.020 · DOI
- Hellstrom, 2002, Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial, J Androl, 23, 763, 10.1002/j.1939-4640.2002.tb02332.x · DOI · Paper page
- Carson, 2004, The efficacy and safety of tadalafil: An update, BJU Int, 93, 1276, 10.1111/j.1464-410X.2004.04819.x · DOI
- Hanson-Divers, 1998, Health outcomes variables important to patients in the treatment of erectile dysfunction, J Urol, 159, 1541, 10.1097/00005392-199805000-00037 · DOI
- Porst, 2003, Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized, controlled trial, Urology, 62, 121, 10.1016/S0090-4295(03)00359-5 · DOI · Paper page
- Young, 2005, Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial, J Androl, 26, 310, 10.2164/jandrol.04126 · DOI
- McMahon, 2004, Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil, J Sex Med, 1, 292, 10.1111/j.1743-6109.04042.x · DOI · Paper page
- McMahon, 2005, Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily-dosed tadalafil for the treatment of erectile dysfunction, J Sex Med, 2, 415, 10.1111/j.1743-6109.2005.20360.x · DOI · Paper page
- Porst, 2006, Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: Results of a multicenter, randomized, double-blind, placebo-controlled trial, Eur Urol, 50, 351, 10.1016/j.eururo.2006.02.052 · DOI · Paper page
- Rajfer, 2007, Tadalafil dosed once a day in men with erectile dysfunction: A randomized, double-blind, placebo-controlled study in the US, Int J Impot Res, 19, 95, 10.1038/sj.ijir.3901496 · DOI
- Hatzichristou, 2008, Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction, Diabet Med, 25, 138, 10.1111/j.1464-5491.2007.02338.x · DOI · Paper page
- Montorsi, 2004, Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction, Eur Urol, 45, 339, 10.1016/j.eururo.2003.11.010 · DOI
- Debusk, 2000, Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of the Princeton consensus panel, Am J Cardiol, 86, 175, 10.1016/S0002-9149(00)00896-1 · DOI · Paper page
- Rosen, 1997, The International Index of Erectile Function (IIEF): A multidimensional scale for the assessment of erectile function, Urology, 49, 822, 10.1016/S0090-4295(97)00238-0 · DOI · Paper page
- Cialis (tadalafil) prescribing information
- Viagra (sildenafil citrate) prescribing information
- Levitra (vardenafil HCl) prescribing information
- Kloner, 2006, Cardiovascular safety update of tadalafil: Retrospective analysis of data from placebo-controlled and open-label clinical trials of tadalafil with as-needed, three times per week, or once-a-day dosing, Am J Cardiol, 97, 1778, 10.1016/j.amjcard.2005.12.073 · DOI · Paper page
- Mittleman, 2003, Clinical trials of sildenafil citrate (Viagra®) demonstrate no increase in risk of myocardial infarction and cardiovascular death as compared with placebo, Int J Clin Pract, 57, 597, 10.1111/j.1742-1241.2003.tb10566.x · DOI
- Wolf, 1992, Epidemiology of stroke, Stroke: Pathophysiology, diagnosis, and management, 3
- Vernet, 2006, Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells, J Sex Med, 3, 84, 10.1111/j.1743-6109.2005.00197.x · DOI
Cited by
Shamloul, R., & Ghanem, H. (2013) · The Lancet · doi:10.1016/s0140-6736(12)60520-0 · Cited by 1,091
Tadalafil in the treatment of erectile dysfunction
Coward, R., & Carson, C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3336 · Cited by 138
Metadata
- Authors
- Porst, H., Rajfer, J., Casabé, A., Feldman, R., Ralph, D., Vieiralves, L. F., Esler, A., Wolka, A. M., & Klise, S. R.
- Affiliations
- Private practice of Urology and Andrology , Hamburg , Germany
- Harbor-UCLA Medical Center , Torrance , USA
- Instituto Médico Especializado , Buenos Aires , Argentina
- Connecticut Clinical Research Center/Urology Specialists , Middlebury , USA
- Institute of Urology , London , UK
- Hospital Naval Marcilio Dias , Rio de Janeiro , Brazil
- ICOS Corporation , Bothell , USA
- Eli Lilly and Company , Indianapolis , USA
- Venue
- The Journal of Sexual Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-09-01
- Volume
- 5
- Issue
- 9
- Pages
- 2160-2169
- ISSN
- 1743-6109
- 1743-6095
- Cited by
- 72
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
